Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib versus standard of care in first-line HER2-mutant advanced non-small cell lung cancer
NL-OMON60983Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Sevabertinib with Standard of care (2 arms). Primary endpoint: Progression-free survival. Started Nov 2024; status: active, not recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60983.